PMID: 8830061Oct 1, 1995Paper

Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment

Journal of Clinical Psychopharmacology
P D KrobothD E Salazar

Abstract

One hundred two healthy men were evaluated in one of three studies conducted to evaluate the coadministration of nefazodone, 200 mg twice daily, and three benzodiazepines: triazolam, 0.25 mg; alprazolam, 1 mg twice daily; or lorazepam, 2 mg twice daily. In the first study, psychomotor performance, memory, and sedation were assessed at 0, 0.5, 1.5, 2.5, and 9 hours after single doses of triazolam alone and again after 7 days of nefazodone. Data from 6 of 12 subjects in this study were evaluable because of a dosing error in the other 6 subjects. In the subsequent two parallel design studies, groups of 12 volunteers received 7 days of either placebo; nefazodone, 200 mg; alprazolam, 1 mg twice daily; or alprazolam plus nefazodone or, in the second study, either placebo; nefazodone; lorazepam, 2 mg twice daily; or lorazepam plus nefazodone; the studies were identical, double-dummy, double-blind designs. Psychomotor performance, memory, and sedation were assessed at 0, 1, 3, and 8 hours after the 8 a.m. dose on days 1, 3, 5, and 7 of the studies. In all studies, blood samples were also obtained at testing times so that effect/concentration comparisons could be made and so full pharmacokinetic analyses could be done for separate studi...Continue Reading

References

Oct 1, 1992·European Journal of Drug Metabolism and Pharmacokinetics·U A ShuklaR H Barbhaiya
Nov 1, 1992·Clinical Pharmacology and Therapeutics·D J GreenblattJ S Harmatz
Jan 1, 1985·British Journal of Clinical Pharmacology·D R AbernethyR I Shader
Apr 1, 1988·Clinical Pharmacology and Therapeutics·L LembergerR F Bergstrom
Mar 1, 1988·Clinical Pharmacology and Therapeutics·P D KrobothR J Erb
Jun 1, 1988·Clinical Pharmacology and Therapeutics·T D BrewertonD C Jimerson
Jan 1, 1987·European Journal of Clinical Pharmacology·D WarotA J Puech
Oct 1, 1986·Journal of Clinical Psychopharmacology·J P PhillipsR B Smith
Jan 1, 1981·Clinical Pharmacology and Therapeutics·F S EbertsR W Vliek
Jan 1, 1983·Psychopharmacology·D R AbernethyR I Shader
Nov 1, 1984·Clinical Pharmacology and Therapeutics·G P StoehrR B Smith
Mar 1, 1984·Clinical Pharmacology and Therapeutics·E H EllinwoodT D Bjornsson
Oct 1, 1980·Journal of Pharmacokinetics and Biopharmaceutics·S Riegelman, P Collier
Jan 21, 1995·Lancet·D J GreenblattC E Wright
Jan 1, 1993·International Clinical Psychopharmacology·L J Frewer, M Lader

Citations

Jan 14, 1998·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·J A Klein, N Kassarjdian
Jul 19, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C Lindsay DeVane
Jan 22, 2003·British Journal of Clinical Pharmacology·S J de VisserJ M A van Gerven
Jun 14, 2006·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·E M HowgateA Rostami-Hodjegan
Jan 6, 2004·Fundamental & Clinical Pharmacology·Edoardo SpinaConcetta D'Arrigo
Nov 19, 2003·Journal of Clinical Psychopharmacology·Michael KotlyarStanley W Carson
Jun 1, 1996·Journal of Clinical Psychopharmacology·L Ereshefsky
Aug 5, 2000·Clinical Pharmacokinetics·E L Michalets, C R Williams
Jun 1, 2002·Drugs & Aging·Edoardo Spina, Maria Gabriella Scordo
Dec 1, 1995·Journal of Clinical Psychopharmacology·D S GreeneR H Barbhaiya
Feb 1, 1997·Journal of Clinical Psychopharmacology·M R MarinoH D Uderman
Feb 1, 2000·Journal of Clinical Psychopharmacology·C LaroudieJ P Decourt
Oct 3, 1999·Journal of Clinical Psychopharmacology·D J GreenblattR I Shader
Jun 2, 2009·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·T TachibanaY Sugiyama
Feb 1, 2000·Journal of Clinical Psychopharmacology·P L BonateC Oo
Aug 22, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·L Roth, G Bertschy
Dec 1, 1995·Journal of Clinical Psychopharmacology·D S GreeneR H Barbhaiya

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Separation Anxiety

Separation anxiety is a type of anxiety disorder that involves excessive distress and anxiety with separation. This may include separation from places or people to which they have a strong emotional connection with. It often affects children more than adults. Here is the latest research on separation anxiety.

KIF1A Associated Neurological Disorder

KIF1A associated neurological disorder (KAND) is a rare neurodegenerative condition caused by mutations in the KIF1A gene. KAND may present with a wide range and severity of symptoms including stiff or weak leg muscles, low muscle tone, a lack of muscle coordination and balance, and intellectual disability. Find the latest research on KAND here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.